Inflectis Bioscience News Today

Nantes, France--(Newsfile Corp. - January 3, 2024) - InFlectis BioScience, a pioneer in developing first-in-class therapies for

(Albany, United States) As per DelveInsight’s assessment, globally, the Amyotrophic Lateral Sclerosis Pipeline constitutes 90+ key companies continuously working towards developing 100+ Amyotrophic Lateral

/PRNewswire/ -- DelveInsights Cough-assisted Devices Market Insights report provides the current and forecast market analysis, individual leading...

The prevalence of amyotrophic lateral sclerosis has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of amyotrophic lateral

/PRNewswire/ -- DelveInsights Amyotrophic Lateral Sclerosis Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed,...

InFlectis BioScience Doses First Patient with IFB-088 in a Phase 2 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

InFlectis BioScience granted Orphan Drug Designation for IFB-088 (icerguastat), a clinical stage treatment for Amyotrophic Lateral Sclerosis

InFlectis BioScience Receives Approval from French Regulatory Authority to Conduct a Phase 2 Clinical Trial for IFB-088 (Icerguastat) for the Treatment of

Clinical Study Demonstrates Promising Results for Investigative ALS Treatment; InFlectis BioScience is Planning Phase 2 Trial of Next-Generation Therapy Reportable 30 Apr 2021, 01:16 GMT+10 Clinical Study Demonstrates Promising Results for Investigative ALS Treatment; InFlectis BioScience is Planning Phase 2 Trial of Next-Generation Therapy Milan, Italy, & Nantes, France -- April 29, 2021 -- A new study shows indications that Amyotrophic Lateral Sclerosis (ALS) may be treated with small molecul...